Long-term efficacy of allergen specific immunotherapy in atopic dermatitis patients in relation to quality of life

European Annals of Allergy and Clinical Immunology

Volumn 47, Issue 1, 2015, Pages 5-9

  Wyrzykowska, Nina ^a   Czarnecka Operacz, M ^b   Adamski, Z ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NONE

Author keywords

Allergen specific immunotherapy; Atopic dermatitis; DLQI

Indexed keywords

ALLERGEN; HOUSE DUST ALLERGEN; POLLEN ANTIGEN;

ADOLESCENT; ADULT; ALLERGEN SPECIFIC IMMUNOTHERAPY; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DERMATOPHAGOIDES; DRUG EFFICACY; FEMALE; FRIEDMAN TEST; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; LONG TERM CARE; MAINTENANCE DRUG DOSE; MALE; OBSERVATIONAL STUDY; POLLEN ALLERGY; QUALITY OF LIFE; SEXUAL BEHAVIOR; SKIN DISEASE; STATISTICAL ANALYSIS; YOUNG ADULT; DERMATITIS, ATOPIC; DESENSITIZATION; MIDDLE AGED; PRESCHOOL CHILD; PSYCHOLOGY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84928698376     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bieber T. Mechanisms of disease. Atopic Dermatitis. N Engl J Med. 2008;358:1483-94.
2. Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;10;7Suppl1:S4.
3. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis-results of a double-blind, placebo-controlled study. Allergologie. 2006;29:171-83.
4. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164-70.
5. Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130(4):925-31.
6. Compalati E, Roqkakou A, Passalacqua G et al. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012 (4):427-33.
7. Bae JM, Choi YY, Park CO et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systemic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132:110-7.
8. Chen SC. Dermatology Quality of Life Instruments: Sorting Out the Quagmire. J Invest Dermatol. 2007;127(12):2695-6.
9. Stephen R. Durham, Emminger W, Kapp A et al. SQ-standarized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized triR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2012;129:717-25.
10. Didier A, Malling HJ, Worm M et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy. 2013;43(5):568-77.